People In Brief
This article was originally published in The Gray Sheet
Executive Summary
Novasys Medical CEO: Renessa non-surgical stress urinary incontinence device maker tapped Scott Cramer as its new CEO last week to replace the departing Debra Reisenthel. Cramer was formerly CEO of peripheral vascular device firm Bacchus Vascular, which Covidien acquired in 2009. Prior to Bacchus, Cramer was a senior VP with varicose vein treatment firm VNUS Medical Technologies, which was also purchased by Covidien last year (1"The Gray Sheet" May 11, 2009). Reisenthel was a nine-year veteran of Novasys. She is pursuing a "position where I can use my leadership and fundraising skills to 'make a difference' and improve people's lives," she says
You may also be interested in...
CMS Proposes Reorg, Names Tavenner Principal Deputy Administrator
CMS' proposed management restructuring, announced internally last week, is intended to improve focus on three areas: program integrity, beneficiary services and strategic planning
Covidien Closes In On Varicose Vein Market With $440 Mil. VNUS Buy
Covidien will bolster its vascular business through the acquisition of varicose vein treatment marketer VNUS for $440 million
East To Meet West On Cardiovascular Clinical Trial Design
FDA and Japanese regulatory authorities will meet in January to discuss a project for establishing "global" cardiovascular device clinical studies capable of satisfying approval requirements in both countries